Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 10:03AM ET
12.00
Dollar change
-0.03
Percentage change
-0.25
%
Index- P/E- EPS (ttm)-4.27 Insider Own27.11% Shs Outstand8.16M Perf Week1.44%
Market Cap128.28M Forward P/E- EPS next Y-3.16 Insider Trans0.00% Shs Float7.80M Perf Month35.14%
Income-37.09M PEG- EPS next Q-1.37 Inst Own11.78% Short Float17.28% Perf Quarter-38.84%
Sales0.00M P/S- EPS this Y-65.77% Inst Trans-3.18% Short Ratio4.61 Perf Half Y27.52%
Book/sh0.74 P/B16.24 EPS next Y38.57% ROA-173.66% Short Interest1.35M Perf Year-38.78%
Cash/sh0.59 P/C20.20 EPS next 5Y- ROE-202.55% 52W Range5.42 - 23.89 Perf YTD-35.83%
Dividend Est.- P/FCF- EPS past 5Y-98.73% ROI-556.99% 52W High-49.77% Beta1.59
Dividend TTM- Quick Ratio2.87 Sales past 5Y0.00% Gross Margin- 52W Low121.40% ATR (14)0.99
Dividend Ex-Date- Current Ratio2.87 EPS Y/Y TTM-23.49% Oper. Margin0.00% RSI (14)62.86 Volatility10.01% 8.84%
Employees5 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price34.60
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q-74.90% Payout- Rel Volume0.78 Prev Close12.03
Sales Surprise- EPS Surprise-49.54% Sales Q/Q- EarningsNov 08 AMC Avg Volume292.59K Price12.00
SMA2022.24% SMA5017.52% SMA2009.40% Trades Volume29,839 Change-0.25%
Date Action Analyst Rating Change Price Target Change
Dec-29-23Initiated Canaccord Genuity Buy $36
Jul-07-21Reiterated Maxim Group Buy $45 → $150
Mar-21-24 09:55AM
Mar-20-24 07:30AM
Mar-18-24 08:52AM
Mar-06-24 03:33PM
Feb-27-24 08:00AM
01:14PM Loading…
Feb-26-24 01:14PM
Feb-14-24 07:30AM
Feb-12-24 04:06PM
Jan-30-24 08:00AM
Jan-24-24 08:00AM
Dec-21-23 04:13PM
Dec-11-23 01:00PM
Dec-05-23 07:30AM
Dec-01-23 11:12AM
07:30AM
07:30AM Loading…
Nov-27-23 07:30AM
Nov-08-23 05:00PM
Nov-02-23 07:30AM
Oct-31-23 08:00AM
Oct-30-23 04:48PM
04:42PM
Oct-24-23 09:13AM
Oct-18-23 08:30AM
Oct-16-23 10:47AM
Oct-13-23 12:42PM
Oct-12-23 11:29AM
11:10AM
08:02AM
Oct-11-23 09:24AM
Oct-10-23 10:24AM
09:49AM Loading…
Oct-09-23 09:49AM
08:52AM
Oct-06-23 12:03PM
07:30AM
Oct-04-23 11:39AM
09:32AM
09:27AM
Oct-03-23 10:45AM
09:43AM
09:11AM
Sep-29-23 12:32PM
Sep-25-23 12:06PM
12:04PM
Sep-22-23 12:00PM
11:57AM
07:57AM
Sep-21-23 01:23PM
09:35AM
Sep-20-23 10:45AM
Sep-19-23 08:30AM
Sep-18-23 01:15PM
11:39AM
Sep-13-23 11:03AM
Sep-12-23 11:56AM
11:49AM
Sep-11-23 02:43PM
Sep-07-23 12:58PM
11:28AM
07:57AM
Sep-06-23 10:31AM
07:46AM
Sep-04-23 12:14PM
Sep-01-23 02:38PM
01:27PM
Aug-30-23 11:51AM
Aug-29-23 11:32AM
Aug-28-23 11:42AM
11:38AM
Aug-24-23 11:50AM
Aug-22-23 10:26AM
09:39AM
Aug-15-23 07:20AM
Jul-28-23 12:56PM
Jul-18-23 08:18AM
Jun-27-23 07:30AM
Jun-20-23 12:05PM
Jun-08-23 07:30AM
May-11-23 07:00AM
May-04-23 09:55AM
Apr-27-23 07:00AM
Apr-25-23 11:36AM
Apr-21-23 10:00AM
07:10AM
Apr-20-23 07:00AM
Apr-19-23 07:30AM
Apr-18-23 10:00AM
09:55AM
08:22AM
Apr-13-23 07:30AM
Apr-11-23 09:04AM
Apr-07-23 12:00PM
Apr-06-23 06:36AM
Apr-03-23 07:30AM
Mar-31-23 11:44AM
Mar-30-23 08:50AM
Mar-29-23 12:27PM
08:17AM
Mar-28-23 10:41AM
09:40AM
Mar-27-23 12:09PM
Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.